Skip to main content

OTCMKTS:KIADF - Kiadis Pharma Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$6.55
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Kiadis Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KIADF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KIADF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Kiadis Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $6.55.

Hold

The current consensus among 3 polled investment analysts is to hold stock in Kiadis Pharma. This rating has held steady since May 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/17/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/3/2020Chardan CapitalDowngradeBuy ➝ Neutral
i
11/3/2020Canaccord GenuityDowngradeBuy ➝ Hold
i
11/2/2020Piper SandlerDowngradeOverweight ➝ Neutral
i
Rating by Edward Tenthoff at Piper Sandler
7/8/2020Piper SandlerUpgradeNeutral ➝ Overweight
i
5/1/2020Canaccord GenuityReiterated RatingBuy
i
6/17/2019Piper Jaffray CompaniesInitiated CoverageOverweight
i
(Data available from 5/16/2016 forward)
Kiadis Pharma logo
Kiadis Pharma N.V., a biopharmaceutical company, develops cell-based immunotherapy products in the field of blood building system. The company develops K-NK002 as an adjunctive immunotherapeutic, which is in Phase II clinical trials for blood cancer patients undergoing a haploidentical HSCT with the post-transplant cyclophosphamide (PTCy) protocol; and K-NK003, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia relapse/refractory (AML R/R). The company's preclinical stage product include K-NK00X, a NK-cell therapy candidate for the treatment of various solid tumors. It has a collaboration agreement with Harbour BioMed, Utrecht University, Erasmus Medical Center, and Viroclinics-DDL for the development of a combination of a monoclonal antibody and natural killer cells as a treatment for COVID-19. Kiadis Pharma N.V. was founded in 1997 and is headquartered in Amsterdam, the Netherlands.
Read More

Today's Range

Now: $6.55
$6.55
$6.55

50 Day Range

MA: $6.55
$6.55
$6.55

52 Week Range

Now: $6.55
$1.72
$6.55

Volume

N/A

Average Volume

2,140 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Kiadis Pharma?

The following sell-side analysts have issued stock ratings on Kiadis Pharma in the last twelve months: Canaccord Genuity, Chardan Capital, and Piper Sandler.
View the latest analyst ratings for KIADF.

What is the current price target for Kiadis Pharma?

0 Wall Street analysts have set twelve-month price targets for Kiadis Pharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Kiadis Pharma in the next year.
View the latest price targets for KIADF.

What is the current consensus analyst rating for Kiadis Pharma?

Kiadis Pharma currently has 3 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in KIADF, but not buy more shares or sell existing shares.
View the latest ratings for KIADF.

How do I contact Kiadis Pharma's investor relations team?

The company's listed phone number is 31 20 240 5250. The official website for Kiadis Pharma is www.kiadis.com.